国邦医药(605507) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥1,176,098,332.11, representing a year-on-year increase of 2.96%[7] - The net profit attributable to shareholders was ¥200,394,843.05, reflecting an increase of 8.26% compared to the same period last year[7] - Total operating revenue for Q1 2022 was RMB 1,176,098,332.11, an increase of 2.5% compared to RMB 1,142,265,947.08 in Q1 2021[28] - Net profit for Q1 2022 reached RMB 200,306,762.89, representing a 8.4% increase from RMB 185,359,261.72 in Q1 2021[30] - Earnings per share for Q1 2022 was RMB 0.36, unchanged from Q1 2021[30] Cash Flow - The net cash flow from operating activities surged by 283.08%, amounting to ¥68,528,706.19, primarily due to increased tax refunds and reduced payments for other operating activities[9] - Cash flow from operating activities for Q1 2022 was RMB 68,528,706.19, significantly higher than RMB 17,888,722.47 in Q1 2021[33] - Net cash inflow from investment activities amounted to ¥1,162,429,657.10, a significant increase compared to ¥2,333,333.73 from the previous period[36] - Cash outflow from investment activities totaled ¥1,188,099,278.00, compared to ¥150,248,614.93 in the prior period, resulting in a net cash flow from investment activities of -¥25,669,620.90, an improvement from -¥147,915,281.20[36] - The net increase in cash and cash equivalents was ¥70,261,999.34, contrasting with a decrease of -¥292,551,015.14 in the prior period[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,759,156,783.71, up 3.28% from the previous year[9] - Total liabilities as of March 31, 2022, were RMB 1,213,156,316.00, compared to RMB 1,167,378,598.11 at the end of 2021, reflecting an increase of about 3.9%[23] - The company's cash and cash equivalents stood at RMB 910,106,181.01, up from RMB 893,006,462.03, indicating a growth of about 1.24%[19] - Accounts receivable increased to RMB 579,134,299.55 from RMB 445,030,444.75, representing a significant rise of approximately 30.1%[19] - Inventory levels rose to RMB 1,408,703,582.09, compared to RMB 1,309,329,113.87, marking an increase of around 7.6%[19] Shareholder Information - The company had a total of 37,071 common shareholders at the end of the reporting period[13] - Major shareholders included Xinchang Ander Trading Co., Ltd. with a 23.08% stake and Xinchang Qingyu Investment Development Co. with a 13.12% stake[13] Equity and Returns - The equity attributable to shareholders increased by 3.16% to ¥6,546,474,291.86 compared to the end of the previous year[9] - The weighted average return on equity decreased by 2.39 percentage points to 3.11%[7] - The company's equity attributable to shareholders reached RMB 6,546,474,291.86, up from RMB 6,346,079,448.81, indicating a growth of approximately 3.15%[23] Expenses - Research and development expenses for Q1 2022 were RMB 31,655,326.74, slightly down from RMB 32,962,901.43 in Q1 2021[28] - Management expenses increased to RMB 65,252,836.36 in Q1 2022 from RMB 55,745,345.68 in Q1 2021, marking a rise of 17%[28] - Financial expenses decreased significantly to RMB 831,313.77 in Q1 2022 from RMB 5,159,934.36 in Q1 2021[28] - The company reported an investment income of RMB 6,011,137.92 in Q1 2022, a recovery from a loss of RMB 445,438.00 in Q1 2021[28]